Merck announced on Friday that a recent study shows that its experimental coronavirus drug, molnupiravir, reduces the risk of serious illness and death in people diagnosed with COVID-19 by at least 50%. Merck and its partner, Ridgeback Biotherapeutics, plan to seek emergency use authorization for th...